Note: Descriptions are shown in the official language in which they were submitted.
CA 02516643 2005-08-19
- 1 -
SPECIFICATION
METHOD FOR PREPARING POLYMORPHISM OF IRINOTECAN HYDROCHLORIDE
Technical Field
The present invention relates to a method for preparing
c-type crystals of irinotecan hydrochloride excellent in the
solubility in water and reduced in the content of impurities.
Background Art
Camptothecin (CPT) is an alkaloid contained in the leaf
or bark of Camptotheca acumination originated from China. CPT
is a substance having excellent antitumor property; however,
hardly soluble in water. Therefore, a semi-synthetic
derivative of CPT, namely, irinotecan hydrochloride
(7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycam
ptothecin hydrochloride (hereinafter sometimes referred to
as "CPT-11") has been developed as a medicament (Japanese
Patent Publication No. 3-4077). Irinotecan hydrochloride
retaining high antitumor properties of CPT and mitigated in
toxicity, has been widely used as an antitumor agent. When
metabolized within the body, irinotecan hydrochloride is said
to convert into 7-ethyl-10-hydroxycamptothecin (SN-38)
(Japanese Patent Publication No. 62-47193), thereby giving
rise to antitumor activity.
Irinotecan hydrochloride is administered to a patient
primarily by intravenous injection. At present, therefore,
CA 02516643 2005-08-19
2 -
irinotecan hydrochloride is sold and used in the form of an
isotonic preparation treated with sorbitol or saline. Up to
now, various attempts have been made to produce a preparation.
For example, JP-A-1995-277981 reports a sustained release
preparation, which is formed by adding a camptothecin
derivative in a copolymer of collagen and 2-hydroxyethyl
methacrylate. JP-A-1998-17472 reports a sustained release
preparation formed by adding camptothecin or its derivative
to a carrier formed of a polylactic acid-glycolic acid
copolymer.
Disclosure of the Invention
Conventionally, amorphous irinotecan hydrochloride and
crystalline irinotecan hydrochloride (b-type crystals) have
been used. However, the amorphous irinotecan hydrochloride
has a problem in that the water content varies depending upon
humidity change during formation of a preparation, varying
dissolution conditions. On the other hand, the crystalline
irinotecan hydrochloride is present in the form oftrihydrates;
however, it is hardly solved in water without raising
temperature. In the circumstances, it has been desired to
develop a methodfor preparing a novel crystalline polymorphic
irinotecan hydrochloride which is excellent in water
solubility and reduced in the content of impurities.
Accordingly, an object of the present invention is to
provide a methodfor preparing a novel crystalline polymorphic
CA 02516643 2005-08-19
3 -
irinotecan hydrochloride which is excellent in the solubility
in water and is reduced in the content of impurities.
The present inventors paid attention to crystalline
polymorphism, a phenomenon where substances having the same
chemical structure show different physical properties such
as different melting points and solubilities. As a result
of intensive studies, they found that a novel crystalline
polymorphic (c-type crystals) irinotecan hydrochloride more
excellent in water solubility than conventional irinotecan
hydrochloride crystallized from water, and low in impurity
content, can be obtained by mixing irinotecan with a
predetermined solvent, adding hydrochloric acid to the mixture
and crystallizing irinotecan hydrochloride. Based on the
finding, the present invention was accomplished.
To be more specifically, a method for preparing c-type
crystals ofirinotecan hydrochloride having diffraction peaks
(20) at 9.15 , 10.000, 11.80 , 12.20 , 13.00 and 13.40 in the
powder X-ray diffractometry characterized by mixing
irinotecan with one or more solvents selected from the group
consisting of acetone, acetonitrile and tetrahydrofuran,
adding hydrochloric acid, and collecting the formed crystals.
The preparation method of the present invention is easily
performed. The c-type crystalline irinotecan hydrochloride
prepared by the invention is excellent in water solubility,
extremely reduced in the content of impurities such as
decomposed matter and prepared without subjecting to a
CA 02516643 2005-08-19
4 -
temperature raising operation, and thus extremely useful as
a basic ingredient of an irinotecan hydrochloride preparation.
Brief Description of the Drawings
Figure 1 is a graph showing an infrared absorption spectrum
of the irinotecan hydrochloride crystals obtained;
Figure 2 is a graph showing thepowderX-raydiffractometry
of the irinotecan hydrochloride crystals obtained;
Figure 3 is a graph showing the results of thermoanalysis
(differential scanning calorimetry) for the irinotecan
hydrochloride crystals obtained;
Figure 4 is a graph showing the infrared absorption
spectrum of a preparation formed by using medicinal carbon
according to Example 3;
Figure 5 is a graph showing the results of thermoanalysis
(differential scanning calorimetry) of a preparation formed
by using medicinal carbon according to Example 3; and
Figure 6 is a HPLC chart of a purity test.
Best Mode of Carrying Out the Invention
Irinotecan
(7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycam
ptothecin) to be used in the present invention can be prepared
by a method disclosed in Japanese Patent Publication No.
3-4077.
As the solvent to be mixed with irinotecan, use may be
made of a solvent mixture of one or two types or more selected
CA 02516643 2005-08-19
- 5 -
from the group consisting of acetone, acetonitrile and
tetrahydrofuran. Furthermore, the solvent to be used in the
present invention is preferably present in the anhydrous form.
The mixing ratio (by weight) of irinotecan to a solvent
is not particularly limited; however, in view of the yield
of c-type crystals, the mixing ratio of a solvent relative
to irinotecan being one part is preferably 30 to 1000 parts
by weight, 50 to 600 parts by weight, particularly 70 to 500
parts by weight.
In mixing irinotecan with a solvent, it is preferable
to add an auxiliary agent for filtration such as medicinal
carbon, activated carbon, Celite, or silica gel. This is
because impurities are easily removed from the raw material
during filtration.
To the mixture of irinotecan and a solvent, hydrochloric
acid is added to produce irinotecan hydrochloride. In this
way, irinotecan is dissolved in the solvent. In theory, the
addition amount of hydrochloric acid should be an equivalent
mole relative to irinotecan; however, in view of the yield
of c-type crystals, 1. 0 to 2. 0 times by mole, 1. 0 to 1. 8 times
by mole, particularly 1. 0 to 1. 5 times by mole is preferable.
The addition temperature is not particularly limited; however,
a temperature of 5 to 30 C, in particular, 12 to 25 C is
preferable.
After hydrochloric acid is added, c-type crystals may
be added as a seed crystals in order to facilitate
crystallization of the c-type crystals of irinotecan
CA 02516643 2005-08-19
- 6 -
hydrochloride. The crystallization conditions are not
particularly limited; however, it is preferable that the
mixture is stirred at 5 to 30 C, further at 10 to 25 C for
2 to 200 hours, and further for 10 to 120 hours.
The c-type crystals of irinotecan hydrochloride thus
formed can be collected by means of filtration or
centrifugation.
The c-type crystals of irinotecan hydrochloride thus
collected may be subjected to a moisture absorption process
performed by a customary method using a saturated aqueous
sodium chloride solution or a saturated aqueous ammonium
nitrate solution.
The irinotecan hydrochloride thus obtained is c-type
crystals, which is more excellent in water solubility than
the b-type crystals crystallized from a supersaturated aqueous
solution of irinotecan hydrochloride. To describe more
specifically, the water solubility of the b-type crystals at
pH3.5 is 11.4 mg/mL, whereas that of the c-type crystals is
100 mg/mL or more.
The c-type crystals has diffraction peaks (20) at 9.15 ,
10.00 , 11.80 , 12.80 , 13.00 and 13.40 , whereas the b-type
crystals has diffraction peaks (20) at 7.60 , 8.30 , 9.55 ,
11.00 and 12.40 , in the powder X-ray diffractometry. Form
this, it is clear that the c-type crystals differs from the
b-type crystals and therefore, the c-type crystals is a novel
crystals polymorphism. Furthermore, the c-type crystals has
an infrared absorption spectrum (v) having peaks at 1757, 1712
CA 02516643 2005-08-19
- 7 -
and 1667 cm-1. In this respect, the c-type crystals differs
from the b-type crystals having peaks at 1748, 1688 and 1663
cm-1. Also, the c-type crystals is irinotecan hydrochloride
sesquihydrates. Note that a peak (20) obtained in the powder
X-diffractometry has an error of 0.2, whereas the infrared
absorption spectrum has an error of about 5 cm-1.
The c-type crystals of irinotecan hydrochloride formed
by the preparation method of the present invention can be used
as an antitumor agent in the same manner as in b-type crystals
of irinotecan hydrochloride formed by a conventional method
and administered by various methods including injections such
as intravenous injection, subcutaneous injection, and
intramuscular injection, and oral administration. In
particular, intravenous administration (injection) and oral
administration are preferable.
In the case of intravenous administration, the dose varies
depending upon the therapeutic purpose; however, a dose of
to 400 mg/adult per day, in particular, 20 to 200 mg/adult
per day, is preferable. In the case of oral administration,
a dose of 50 to 2, 000 mg/adult, in particular, 100 to 1, 000
mg/adult per day, is preferable.
In the case of oral administration, a preparation is
preferably formed such that it can be suitably absorbed from
the gastrointestinal tract. Examples of such a form include
tablets, powders, capsules, or soft capsules, and peroral
liquid preparations such as an aqueous suspension solution,
solution, and syrup. In the case of injection, an ample of
CA 02516643 2005-08-19
- 8 -
a predetermined dose is preferable. To such a preparation,
a preservative or the like may be used.
Examples
The present invention will be described in more detail
below by way of examples, which should not be construed as
limiting the present invention.
Example 1
Irinotecan was suspended in acetonitrile or acetone in
accordance with the amounts shown in Table 1 and dissolved
by adding, 6mol/L hydrochloric acid. To each mixture solution,
1 mg of c-type crystals separately prepared was added and the
solution was stirred at 22 C for 25 to 46 hours. The formed
crystals were obtained by filtration, dried under reduced
pressure, and subjected to a moisture absorption process
performed by a saturated aqueous sodium chloride solution
method until the crystals showed constant weight (about 80
hours) . In this manner, the crystals of irinotecan
hydrochloride were obtained.
Table 1 shows the results of the preparations.
Table 1
No. Irinotecan Solvent) Hydro- Seed Crystalli- Yield
(g) Acetonitrile Acetone chloric crystals zation time (s)
acid2 (hour)
1 5.0 80 1.0 - 46 83.4
2 5.0 120 1.0 c form 25 80.5
3 10.0 120 1.05 c form 41 76.3
4 1.0 360 1.05 c form 41 91.7
1) mL/g (Irinotecan)
2) Times by mole relative to irinotecan
CA 02516643 2005-08-19
- 9 -
The crystals of irinotecan hydrochloride obtained above
were subjected to infrared absorption spectrum analysis,
powder X-ray diffraction analysis, and thermoanalysis. The
results are shown in Figures 1 to 3.
In the infrared absorption spectrum, strong absorption
was observed at wavelengths of about 1757 cm-1, 1712 cm-1, 1667
cm -1 (Figure 1) .
In the powder X-ray diffraction, diffraction peaks (20)
were observed at 9.15 , 10.00 , 11.80 , 12.20 , 13.00 and
13.40 ; however no strong peak was observed at 11. 000, which
is intrinsic to the b-type crystals (Figure 2).
In the thermoanalysis (differential scanning
calorimetry) , an endothermic peak near 90 C due to dehydration
was not observed, which is intrinsically observed in the b-type
crystals (Figure 3).
The moisture content of the crystals was measured by the
Karl Fischer method. As a result, the moisture content of
No.3 was 3.96%. Therefore, it turned out that the crystals
above were obtained in the form of sesquihydrates (calculation
value: 4.150).
From the results above, it was confirmed that the crystals
of irinotecan hydrochloride prepared in accordance with Nos.
1 to 4 are c-type, which are different from the b-type crystals
conventionally crystallized from water.
Example 2
The irinotecan hydrochloride prepared in Example 1 was
measured for water solubility and stability over time.
CA 02516643 2005-08-19
- 10 -
Note that irinotecan hydrochloride b-type crystals was
formed as a comparative product in accordance with the
following method.
Formation of a comparative product (b-type crystals)
Ten grams of irinotecan was suspended in about 100 mL
of purified water. About 10 mL of diluted hydrochloric acid
(the Japanese Pharmacopoeia) was added dropwise to the
suspension solution while stirring. Then, irinotecan was
dissolved by raising temperature of the suspension solution.
After the resultant solution was filtered, a seed crystals
was added to the filtrate, which was stirred at room temperature
for about 50 hours to form crystals. The resultant crystals
were subjected to suction filtration and a filtrated product
was dried under reduced pressure. A dried product was allowed
to stand still in a humidifier to humidify in accordance with
a saturated aqueous sodium chloride solution method.
Solubility measurement
About 0.5 g of b- or c-type crystals were weighed out,
suspended in a preparation solution, and shaken at 22 C for
30 minutes (130 r/min) . The mixture was filtered by a membrane
filter (0.45 m). To 1 ml of the filtrate, the preparation
solution was added up to 200 mL. 10 l was aliquoted and
analyzed by liquid chromatography. The dissolution amount
was obtained on the basis of a calibration curve previously
prepared.
Note that the preparation solution used herein was
prepared by dissolving 45 g of D-sorbitol in an appropriate
CA 02516643 2005-08-19
- 11 -
amount of distilled water for injection, adding 900 mg of lactic
acid, adjusting pH of the solution at about 3.5, and adding
distilled water for injection up to 1000 mL.
The c-type crystals of No. 3 according to the present
invention was dissolved upon adding the preparation solution
and provided a dissolution amount of 100 mg/mL or more, meaning
that they are extremely easily dissolved in water, whereas,
the b-type crystals (a comparative product) exhibited a
dissolution amount of 11.4 mg/mL. Accordingly, it was
demonstrated that the c-type crystals prepared by the method
according to the present invention is extremely excellent in
water solubility compared to the b-type crystals.
Change of dissolution state over time
The b- or c-type crystals was dissolved in a preparation
solution to a concentration of 30 mg/mL and filtered by a
membrane filter (0.22 m). The filtrate was aliquoted and
allowed to stand still at 22 C in the dark.
The c-type crystals (No. 3) prepared by the method of
the present invention was dissolved at room temperature by
shaking for 1 to 2 minutes, whereas, the b-type crystals was
not dissolved until the solution was heated to about 70 C and
shaken for severalminutes. The filtrates of c-type and b-type
crystals were both stable in 3 months or more. Neither
color-tone change (yellowing change) nor precipitation was
observed.
Stability test over time
CA 02516643 2005-08-19
- 12 -
The c-type crystals (Example 1, No. 3) was placed in
lightproof airtight containers (screw-top brown vial shielded
by a Parafilm) and stored in a laboratory (about 15 C) and
a refrigerator (about 5 to 10 C) and thereafter subjected to
infrared absorption spectrum analysis, thermoanalysis, and
Karl Fischer analysis for measuring a moisture content. As
a result, no change was observed in comparison with the state
before storage.
Example 3
One gram of irinotecan was added to 120 mL of
tetrahydrofuran. The resultant solution was stirred for 30
minutes in the presence or absence of 0.2 g of medicinal carbon.
The medicinal carbon was filtered off by a membrane filter.
While stirring the filtrate, 6 mol/L hydrochloric acid was
added in an amount 1.05 times by mole as large as irinotecan
and subjected to the same process as in Example 1. Note that
the moisture absorbing time until the solution reached constant
weight was about 100 hours. The results of infrared absorption
spectrum and thermoanalysis (differential scanning
calorimetry) for crystals obtained in asystem having medicinal
carbon added thereto are shown in Figures 4 and S. It was
confirmed that the obtained crystals is c-type crystals.
The yield of the c-type crystals was 85.6% in the case
where medicinal carbon was added and 100% in the case where
no medicinal carbon was added.
Example 4: Purity test
CA 02516643 2005-08-19
- 13 -
The c-type crystals prepared by the method of the present
invention and the b-type crystals prepared as a comparative
product in Example 2 were subjected to a purity test in
accordance with the following method.
Purity test: To 0.05 g of the c-type or b-type crystals,
a solution mixture containing 0. 01 mol/L potassium dihydrogen
phosphate, methanol and acetonitrile in a ratio of 6:4:3 was
added to prepare a sample solution of 20 mL. A 1-ml aliquot
was accurately taken from the sample solution. Tothealiquot,
the solution mixture containing 0.01 mol/L potassium
dihydrogen phosphate, methanol and acetonitrile in a ratio
of 6:4:3 was added to prepare a standard solution of exactly
100 mL. An aliquot of 20 L was taken from each of the sample
solution and the standard solution and subjected to HPLC to
determine the contents of analogous substances in the following
operation conditions.
The total content of analogous substances (%) = (the peak
areas of substances except for irinotecan hydrochloride in
the sample solution)/(the peak area of irinotecan
hydrochloride in the standard solution)
The content of each analogous substance ( o) _ (the peak
area of each analogous substance in the sample solution) / (the
peak area of irinotecan hydrochloride in the standard
solution).
Operation conditions for HPLC
CA 02516643 2005-08-19
- 14 -
Mobile phase: Solution mixture of 0.01 mol/L potassium
dihydrogen phosphate/methanol/acetonitrile (6:4:3)
containing 0.005 mol/L sodium 1-decane sulfonate.
Detection: an ultraviolet absorptiometer (measurement
wavelength: 254 nm)
Column: InertsilODS-2 (5 m; 4.6 mmlD x 25 cm)
Column temperature: a constant temperature of about 40 C
Flow rate: about 1 mL/min
The results of the purity test are shown in Figure 6 and
Table 2.
Based on the HPLC retaining time, analogous substances
contained in irinotecan hydrochloride were determined as
follows. A substance showing retention time (RT) of 6.4
minutes was determined as 7-ethyl-l0-hydroxycamptothecin, a
substance of 10.1 minutes as a decomposed product (X2) and
a substance of 16.1 minutes as a decomposed product (Xl).
The b-type crystals of irinotecan hydrochloride
(comparative product) contained decomposed products (Xl and
X2) in an amount of 0. 17 o byweight, whereas, the c-type crystals
of irinotecan hydrochloride prepared by the method of the
present invention had the decomposed products in an amount
as low as 0.03 to 0.04 % by weight, suggesting that the purity
of the c-type crystals according to the present invention is
high.
CA 02516643 2005-08-19
- 15 -
Table 2
(weight %)
c-type crystals
Retaining time
(minute) Example 1 Example 3 b-type crystals
No.3 using carbon
6.4 0.03 0.01 0.01
10.0 0.03 0.03 0.12
16.1 <0.005 0.01 0.05
(Analogous substances )3~ 0.23 0.22 0.36
3) Total content of analogous substances each having different
retention time
